Press coverage about Rexahn Pharmaceuticals (NYSEMKT:RNN) has been trending somewhat negative this week, AlphaOne Sentiment Analysis reports. The research firm, a service of Accern, identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rexahn Pharmaceuticals earned a daily sentiment score of -0.04 on AlphaOne’s scale. AlphaOne also assigned media headlines about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Here are some of the media headlines that may have impacted AlphaOne Sentiment’s rankings:

Insider Buying and Selling by Quarter for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Several brokerages recently commented on RNN. HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, June 5th. FBR & Co set a $14.00 price target on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 26th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $19.50 price target on shares of Rexahn Pharmaceuticals in a research note on Friday, June 9th.

Shares of Rexahn Pharmaceuticals (NYSEMKT RNN) traded down 0.66% during midday trading on Friday, reaching $3.03. The company’s stock had a trading volume of 147,667 shares. Rexahn Pharmaceuticals has a 12 month low of $0.13 and a 12 month high of $4.74. The company has a 50-day moving average price of $3.24 and a 200-day moving average price of $1.04. The firm’s market cap is $77.03 million.

In other Rexahn Pharmaceuticals news, Director Chang Ho Ahn sold 250,000 shares of the firm’s stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $0.70, for a total value of $175,000.00. Following the completion of the transaction, the director now directly owns 6,260,000 shares in the company, valued at $4,382,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

WARNING: “Rexahn Pharmaceuticals (RNN) Earning Somewhat Negative Press Coverage, Study Shows” was originally reported by Financial Market News and is the sole property of of Financial Market News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.